Uncategorized
KRAS drugmakers take another, better swing at lung cancer
SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.
KRAS mutations drive around a quarter of all cancer cases and …